The Russian Direct Investment Fund (RDIF) and the Chinese TopRidge Pharma (a division of Tibet Rhodiola Pharmaceutical Holding) have entered into an agreement of the production in China of more than 100 million doses per year of the Sputnik V coronavirus vaccine, the fund reports.
This volume of production will provide vaccination for more than 50 million people. RDIF and TopRidge Pharma also agreed to cooperate in the registration and further promotion of the vaccine in China.
TopRidge Pharma will be eligible to distribute the vaccine to mainland China, as well as Hong Kong, Macau and Taiwan after regulatory approval.
“The partnership with Tibet Rhodiola will expand the production capabilities for the production of the Sputnik V vaccine in China and ensure the supply of the drug to partners to defeat the pandemic. China is one of the largest hubs for the production of the Sputnik V drug, and we are ready to expand partnerships with manufacturers in the country to meet the growing demand for the Russian vaccine. The Sputnik V vaccine with an efficiency of 91.6% is one of the best tools for fighting coronavirus in the world, “said Kirill Dmitriev, CEO of the RDIF.
The Sputnik V vaccine is registered in 58 countries with a total population of over 1.5 billion people. Its efficacy is 91.6%, as confirmed by the publication of data, in The Lancet, one of the oldest and most respected medical journals in the world. The drug is built on a well-studied platform of human adenoviral vectors and uses two different vectors for two vaccinations during vaccination, providing longer immunity than vaccines using the same delivery mechanism for both vaccinations.
